Pain Management

The human aging process can be characterized by progressive cellular degeneration, mitochondria malfunctioning, inflammatory responses, epigenetics modifications, and loss of tissue regenerative ability. The recent progress made in the field of longevity has revealed several promising treatment opportunities for prolonging a healthy lifespan in humans through epigenetics regulation, senolytics application, NAD+ precursors' intake, telomerase activation, and regenerative treatments. This review considers evidence from human studies about the impact of DNA methylation, cell senescence elimination, mitochondria recovery, enhanced immunity, tissue renewal, and cognitive reserve increase in human aging biology. According to findings based on human research, interventions involving senolytic compounds, Nicotinamide Riboside (NR), Nicotinamide Mononucleotide (NMN), and telomerase-linked regenerative treatment have the ability to contribute to improved metabolism, vascular functions, immunological resilience, and cognitive efficiency while reducing inflammatory processes and decreasing the number of senescent cells in a human body. In addition, comprehensive longevity approaches consisting of the mentioned interventions seem to possess combined benefits in terms of human longevity improvement. However, there are certain drawbacks that must be addressed when applying these interventions into clinical practice; namely, small sample sizes used in studies, lack of long-term safety testing, ethical issues, and inadequate biomarkers. Future directions in the research are discussed.

Hypertension is a major cause of morbidity and mortality worldwide and requires the development of better drug delivery methods to help maintain long-term drug control. Nifedipine is designed as a dihydropyridine calcium channel blocker but is hampered by inadequate aqueous solubility, thorough first pass metabolism, and short biological half-life. Liposomal nanocarriers, especially elastic and deformable vesicles, have been discovered as potential systems to overcome the limitations. This systematic review and meta-analysis assess the efficacy of liposome formulations in improving the delivery of nifedipine, specifically entrapment efficiency, nifedipine permeation, release kinetics and therapeutic outcomes. Statistic and systematic search of "sur varieties and performance" Eligible studies were identified by systematic search of the literature in PubMed, Scopus and Web of science since 2015-2025. Quantitative synthesis was shown to provide much greater entrapment efficiency (+18.6%), peak permeation rates (standardized mean difference: 1.42) and drug release profiles over time than conventional formulations. Elastic liposomes always outperformed regular liposomes in terms of transdermal delivery and stability. The results confirm that liposomal nanocarriers are substantially able to improve the bioavailability and therapeutic performance of nifedipine, and also provide support for the potential of nifedipine as an antihypertensive drug in an advancement treatment.